Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines
- PMID: 11006018
- DOI: 10.1006/cimm.2000.1693
Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines
Abstract
With a new flow cytometric cytotoxicity assay, we examined the mechanism of action of chimeric mouse human anti-CD20 monoclonal antibody IDEC-C2B8. IDEC-C2B8 alone induced direct cytotoxicity in four of eight examined CD20-expressing lymphoma cell lines (RAJI, DAUDI, JOK-1, and WT100) at a concentration above 100 ng/ml. Moreover, after 4 h incubation in human serum, only a moderate complement-dependent cellular cytotoxicity (CDCC) was observed, whereas cytotoxicity increased markedly after 3 days of culture, indicating that combined direct cytotoxicity and CDCC were responsible. IDEC-C2B8 induced an effective antibody-dependent cellular cytotoxicity (ADCC) in seven of eight tested lymphoma cell lines when peripheral blood mononuclear cells were used as effector cells. ADCC was moderately enhanced by cytokine interleukin-2, whereas interleukin-12, interferon-alpha, and GM-CSF had no influence. Interestingly, we could demonstrate a correlation between CD32 expression on lymphoma cell lines and IDEC-C2B8-induced direct cytotoxicity, indicating that crosslinking of CD20 with CD32 may be involved in the mechanism of cytotoxicity. We propose that direct cytotoxicity, CDCC, and ADCC result in the marked elimination of CD20-expressing tumor cells observed after treatment with IDEC-C2B8.
Copyright 2000 Academic Press.
Similar articles
-
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.Haematologica. 2002 Jan;87(1):33-43. Haematologica. 2002. PMID: 11801463
-
Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.Cancer Res. 2008 Apr 1;68(7):2400-8. doi: 10.1158/0008-5472.CAN-07-6663. Cancer Res. 2008. PMID: 18381448
-
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.Cancer Biother Radiopharm. 1997 Jun;12(3):177-86. doi: 10.1089/cbr.1997.12.177. Cancer Biother Radiopharm. 1997. PMID: 10851464
-
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.Oncogene. 2005 Mar 24;24(13):2121-43. doi: 10.1038/sj.onc.1208349. Oncogene. 2005. PMID: 15789036 Review.
-
Mechanism of action of rituximab.Anticancer Drugs. 2001 Jun;12 Suppl 2:S1-4. Anticancer Drugs. 2001. PMID: 11508930 Review.
Cited by
-
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Exp Mol Med. 2011 Oct 31;43(10):539-49. doi: 10.3858/emm.2011.43.10.063. Exp Mol Med. 2011. PMID: 21811090 Free PMC article. Review.
-
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.MAbs. 2010 Jan-Feb;2(1):14-9. doi: 10.4161/mabs.2.1.10789. Epub 2010 Jan 30. MAbs. 2010. PMID: 20081379 Free PMC article. Review.
-
Rituximab: mechanism of action.Semin Hematol. 2010 Apr;47(2):115-23. doi: 10.1053/j.seminhematol.2010.01.011. Semin Hematol. 2010. PMID: 20350658 Free PMC article. Review.
-
Treatment with rituximab in benign and malignant hematologic disorders in children.J Pediatr. 2007 Apr;150(4):338-44, 344.e1. doi: 10.1016/j.jpeds.2006.12.038. J Pediatr. 2007. PMID: 17382107 Free PMC article. Review. No abstract available.
-
Technetium-99m-labeled rituximab for use as a specific tracer of sentinel lymph node biopsy: a translational research study.Oncotarget. 2016 Jun 21;7(25):38810-38821. doi: 10.18632/oncotarget.9614. Oncotarget. 2016. PMID: 27246977 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
